In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Long term follow-up results of adult operated ToF patients

Session Poster Session 1

Speaker Umit Yasar Sinan

Congress : Acute Cardiovascular Care 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure - Clinical
  • Session type : Poster Session
  • FP Number : P274

Authors : U Y Sinan (Istanbul,TR), O Onder (Istanbul,TR), MS Kucukoglu (Istanbul,TR)

15 views

Authors:
U Y Sinan1 , O Onder1 , MS Kucukoglu1 , 1Istanbul University Cardiology Institute, Department of Cardiology - Istanbul - Turkey ,

Citation:

Background: Tetralogy of Fallot consists 10% of all congenital cardiac anomalies. We aimed to review the long term clinical and echocardiographical data, presence of arrhythmias, assessment of ventricular function of patients with operated tetralogy of Fallot.
Methods: We retrospectively reviewed the medical records of operated tetralogy of Fallot patients that was followed up at adult congenital heart disease outpatient clinic of our university hospitalal between January 2015 and June 2017.  

Results: The mean age of study populations was 32,7±10,2 years old (range between 14-66 years old). There were 33 women (58.9%) and 23 men (41.1%) (N:56). The total correction operation age was mean 6,3±4.85 years old (range between 6 months and 30 years old). The mean follow up ranges between 9 and 45 years. According to 24 hour ambulatory holter recordings, 8 patients (14.3%) had supra-ventricular tachycardia (SVT), 7 patients (12.5%) had non-sustained ventricular tachycardia (VT). The mean NT-proBNP level was ranged between 17-623 pg/ml. On TTE,  mean TAPSE was 17 ± 2 mm. Mean tricuspid annulus peak S’ velocity was 10,3 ± 2,4 mm. Pulmonary regurgitation was severe in 4 patients (7.1%), moderate in 9 (16.1%) patients and mild in 43 patients (76.8%). There was no statically significant correlation between RVEF and severity of PR. The correlation analysis between RV function (TAPSE, TAPSE and S’) and BNP showed correlation coefficient was 0.11 (p:0.47) between  BNP and FAC; 0.32 (p:0.42) BNP and TAPSE; and 0.01 (p:0.92) BNP and S’. There was only correlation between TAPSE and BNP (r=0,38, p=0,04). There was no difference between patients with normal RV function and with RV dysfunction in the meaning of QRS duration and mean BNP level.

Conclusion: After total correction of ToF, patients should be followed up for progression PR, presence of RV dysfunction, RVOT obstruction and arrhythmias. Re-operation may be necessary within years. BNP is also useful follow up parameters to diagnose RV dysfunction earlier.

Parameter Correlation BNP (pg/ml) QRS (msn)
FAC (%, mean±SD)

Coefficient

P value

0,11

0,47

-0,19

0,15

TAPSE (mm, mean±SD)

Coefficient

P value

0,32

0,04

-0,11

0,40

S' (cm/sn, mean±SD)

Coefficient

P value

0,01

0,92

-0,15

0,25

Correlation between RV systolic function parameters and BNP, QRS duration

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are